Clinical trials: Arts
HIV-1 Infection
A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)
The primary objectives of this study are to evaluate the safety and tolerability of a switch to Doravirine/Islatravir (DOR/ISL) compared with continued baseline antiretroviral therapy (ART), through Week 48; and to evaluate the…
- Trial name
- NCT05631093
- Testing
- ART, DOR/ISL
- Where
- 53 sites in United States, Australia and 6 more
- Volunteers
- 553 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infection
Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
The overall objective is to determine the influence of timing of ART initiation and alcohol consumption on HIV disease course. ART initiation immediately after HIV infection largely results in smaller HIV reservoir and lower…
- Trial name
- MERLIN (NCT02744040)
- Testing
- ART initiation at time of HIV diagnosis, ART at 24 weeks
- Where
- Peru
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
Infection, Human Immunodeficiency Virus
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
This study will be conducted in approximately 468 HIV-1 infected antiretroviral therapy (ART)-naïve subjects. Subjects will be randomized 1:1 to receive dolutegravir (DTG) 50 mg once daily (approximately 234 subjects) or…
- Trial name
- FLAMINGO (NCT01449929)
- Testing
- dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
- Where
- 66 sites in United States, France and 7 more
- Volunteers
- 488 people
- Sponsor
- ViiV Healthcare
HIV-1 Infection
The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART
The purpose of this study is to compare HIV RNA expression and infection within resting (CD4)+ cells in HIV-infected patients on stable ART before and after a single exposure to Vorinostat (VOR), after exposure to short intervals…
- Trial name
- NCT01319383
- Testing
- Vorinostat
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Infertility, Female
Multicenter, Randomized, Open Label, Parallel Study to Evaluate the Efficacy & Safety of IVF-M HP Inj. vs. Menopur® Inj.
The objective of this study was to demonstrate the non-inferiority of IVFM HP Inj. by evaluating its efficacy versus Menopur® Inj.
- Trial name
- NCT02458768
- Testing
- IVF-M HP Inj., Menopur® Inj.
- Volunteers
- 112 people
- Sponsor
- LG Life Sciences
Cultural Competency, Personal Reflection
Impact of Visual Arts Immersion
The purpose of this study is to enhance engagement, coping and self-reflection by attuning nurses to creative and observational skills drawn from a visual arts pedagogical framework.
- Trial name
- NCT05877976
- Testing
- Visual Arts Immersion
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Infection, Human Immunodeficiency Virus
A Study to Assess Dolutegravir in HIV-infected Subjects With Treatment Failure on an Integrase Inhibitor Containing Regimen.
The purpose of this trial is to assess the antiviral activity and safety of a dolutegravir (DTG) containing regimen in HIV-1 infected, antiretroviral therapy (ART)-experienced adults with current or historical failure on an…
- Trial name
- VIKING-3 (NCT01328041)
- Testing
- dolutegravir
- Where
- 89 sites in United States, Belgium and 5 more
- Volunteers
- 183 people
- Sponsor
- ViiV Healthcare
Infertility
A Dose-response Trial Using rFSH FE 999049 in Women Undergoing IVF/ICSI Treatment
This trial investigates the effects of several doses of FE 999049 in women undergoing IVF/ICSI (in-vitro fertilisation/intracytoplasmic sperm injection) treatment.
- Trial name
- NCT01426386
- Testing
- FE 999049, Gonal - F
- Where
- 8 sites in Belgium, Czechia and 2 more
- Volunteers
- 265 people
- Sponsor
- Ferring Pharmaceuticals
Human Immunodeficiency Virus, Immune Reconstitution Inflammatory Syndrome
Pediatric Urgent Start of Highly Active Antiretroviral Treatment (HAART)
Design: Randomized clinical trial involving hospitalized HIV-1 infected children. Children will be randomized to randomized to urgent (<48 hours) versus early antiretroviral therapy (7-14 days). This trial will be unblinded.
- Trial name
- PUSH (NCT02063880)
- Testing
- Urgent ART, Early ART
- Where
- 4 sites in Kenya
- Volunteers
- 183 people
- Sponsor
- University of Washington
Parkinson Disease
Kick Out Parkinson's Disease 2
The benefits of exercise for general health and well-being in older adults are well-established. Balance exercises such as tai chi and yoga, along with resistance training, can improve or maintain physical function in older…
- Trial name
- NCT03882879
- Testing
- Karate Classes, Pre-Intervention Study Visit, Bimonthly Online Survey
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Rush University Medical Center
HIV Infections, Substance Use Disorders
Couples ART Adherence Intervention for PWID in Kazakhstan
The fastest growing HIV epidemics globally are driven by injection drug use, but only a small percentage of HIV-positive people who inject drugs (PWID) have achieved viral suppression.
- Trial name
- NCT03555396
- Testing
- SMART Couples 2, Standard of Care
- Where
- Kazakhstan
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Columbia University
Risk Reduction
Urine Tenofovir Point-of-care Test to Identify Patients in Need of ART Adherence Support (UTRA Study)
ART is given to people living with HIV in order to suppress the virus, resulting in improved health for the individual and decreased transmission of the virus to others. Success of ART is dependent on adherence.
- Trial name
- NCT05333679
- Testing
- UTRA, UTRA feedback
- Where
- South Africa
- Volunteers
- 200 people
- Sponsor
- University of California, San Francisco
Reproductive Techniques, Assisted
Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle
The present study was designed to investigate, in hyporesponder subjects, that required in a previous assisted reproductive technologies (ART) cycle follicle stimulating hormone (FSH) >3500 International Unit (IU), the…
- Trial name
- Luveris in ART (NCT01071200)
- Testing
- Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH), r-hFSH
- Where
- Italy
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Breast Cancer Female, Depressive Symptoms
The Role of Emotional Processing in Improving the Quality of Life of Breast Cancer Patients
The purpose of this study is to examine two mechanistic changes: emotion processing (awareness, expression and acceptance) and cholinergic anti-inflammatory processes (HRV and cytokine expression) through which an Art Therapy…
- Conditions
- Breast Cancer Female, Depressive Symptoms, Fatigue, Pain
- Trial name
- REPAT (NCT03377816)
- Testing
- Art Therapy
- Where
- Israel
- Volunteers
- 318 people
- Sponsor
- University of Haifa
Cryptococcal Meningitis, HIV Infections
Cryptococcal Optimal ART Timing Trial
The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to…
- Conditions
- Cryptococcal Meningitis, HIV Infections, AIDS
- Trial name
- COAT (NCT01075152)
- Testing
- efavirenz, nucleoside
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 177 people
- Sponsor
- University of Minnesota
Acquired Immunodeficiency Syndrome
Pharmacokinetics of Lopinavir/Ritonavir at Three Different Doses.
The purpose of this study is to assess the pharmacokinetics of plasma lopinavir/ritonavir over a 12-hour dosing interval, following administration to male and female HIV-negative healthy volunteers of: 1.
- Trial name
- ENCORE3 (NCT00985543)
- Testing
- lopinavir/ritonavir
- Where
- United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kirby Institute
Tobacco Use Disorder, Homelessness
Abstinence Reinforcement Therapy (ART) for Homeless Veteran Smokers
The goal of this research study is to examine the effects of a treatment for helping homeless veterans who smoke to stop smoking. Participants in the study will be assigned to one of two study groups.
- Trial name
- NCT02245308
- Testing
- Nicotine Patches, mobile contingency management (mCM), Smoking cessation counseling
- Where
- United States
- Volunteers
- 133 people
- Sponsor
- VA Office of Research and Development
HIV Infections, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)
This is a study that will investigate the safety and efficacy of an investigational drug in Human immunodeficiency virus (HIV) infected patients.
- Trial name
- NCT00100048
- Testing
- Comparator: MK0518 monotherapy, Comparator: MK0518 combination therapy, Comparator: efavirenz
- Volunteers
- 206 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1 Infection
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART.
- Trial name
- NCT02440789
- Testing
- Sirolimus
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV Vaccine, HIV-1-infection
Safety and Immunogenicity of HIV-1 Vaccines C62-M4 or C1C62-M3M4 in Persons With HIV-1 Suppressed on ART
This is a double blind, randomized, placebo-controlled, parallel design study in which 18 in participants with HIV (PWH) on suppressive antiretroviral therapy will be randomly assigned to receive vaccination with C62 followed by…
- Trial name
- CM HIV-CORE008 (NCT05604209)
- Testing
- ChAdOx1.HIVconsv62, ChAdOx1.tHIVconsv1, MVA.tHIVconsv4
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of North Carolina, Chapel Hill